Metabolic Syndrome, Cardiovascular Disease and the Hair Growth Cycle: Addressing hair growth disruptions using Nourkrin® with Marilex® as a proteoglycan replacement therapy: A concise review
Open Access
- 23 May 2018
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 2 (1), 001-007
- https://doi.org/10.29328/journal.adr.1001004
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Metabolic syndrome and skin: Psoriasis and beyondIndian Journal of Dermatology, 2013
- Is prediabetes risk factor for hair loss?Medical Hypotheses, 2012
- Sex hormone–binding globulin and risk of hyperglycemia in patients with androgenetic alopeciaJournal of the American Academy of Dermatology, 2011
- Androgenetic alopecia and insulin resistance: are they truly associated?International Journal of Dermatology, 2011
- Chemotherapy-induced alopeciaCurrent Opinion in Supportive & Palliative Care, 2010
- Association of androgenetic alopecia with metabolic syndrome in men: a community-based surveyBritish Journal of Dermatology, 2010
- Androgenic alopecia and insulin resistance: are they really related?Clinical and Experimental Dermatology, 2009
- Nourkrin®: Objective and Subjective Effects and Tolerability in Persons with Hair LossJournal of International Medical Research, 2006
- Versican expression by dermal papilla‐regenerated hair follicles – a promising tool for hair‐regrowth productsInternational Journal of Cosmetic Science, 2004
- Early androgenetic alopecia as a marker of insulin resistanceThe Lancet, 2000